The SLC16A14 antibody targets the solute carrier family 16 member 14 (SLC16A14), a transmembrane protein belonging to the monocarboxylate transporter (MCT) family. SLC16A14 is implicated in the transport of monocarboxylates, such as lactate, pyruvate, and ketone bodies, across cellular membranes, playing a potential role in metabolic regulation and energy homeostasis. Though less characterized than other MCTs (e.g., MCT1 or MCT4), SLC16A14 is hypothesized to contribute to tissue-specific substrate shuttling, particularly in organs like the liver, testes, and thyroid. Its expression patterns and physiological roles remain under investigation, with studies suggesting links to metabolic disorders, cancer progression, and thyroid dysfunction.
SLC16A14 antibodies are essential tools for elucidating the protein’s expression, localization, and function. These antibodies are typically validated in applications such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect endogenous SLC16A14 in research models. Specificity is critical, as cross-reactivity with other MCT family members must be ruled out. Recent research has explored SLC16A14’s potential as a biomarker or therapeutic target, particularly in contexts of altered metabolism. However, comprehensive mechanistic insights remain limited, underscoring the need for further studies using reliable antibody reagents.
[UniProt ID: Q7RTY0; Gene ID: 162515]